W
WAVEMAN · COMPANY
CVKD · Cadrenal Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

CVKD

Cadrenal Therapeutics, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001937993
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-$388.3K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
11
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$388.3K over 180 days
-$272.9K over 90 days · -$388.3K of it by a 10%+ holder
below 53% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
11 funds added or opened last quarter
below 81% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
1.7% of shares outstanding short · 1.2 days to cover · settled 2026-07-31
below 67% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -90.2%
-90.2%12M
-90%-55%-20%+14%2025-092025-102025-122026-032026-052026-072026-09 2025-09-25 · Szot Matthew K sold $153.1K2025-09-25 · Pham Quang X sold $95.7K2025-12-29 · Szot Matthew K sold $69.2K2026-06-09 · Pham Quang X sold $52.7K2026-06-12 · Pham Quang X sold $51.2K2026-05-11 · Pham Quang X sold $37.3K2025-09-24 · Pham Quang X sold $36.1K2026-06-22 · Pham Quang X sold $32.5K2026-06-26 · Pham Quang X sold $27.5K2026-06-08 · Pham Quang X sold $25.8K2025-10-13 · Pham Quang X sold $25.5K2025-10-13 · Szot Matthew K sold $25.3K2025-10-09 · Pham Quang X sold $25.2K2025-10-27 · Szot Matthew K sold $25.2K2025-10-24 · Szot Matthew K sold $25.2K2025-10-01 · Szot Matthew K sold $23.8K2025-10-09 · Szot Matthew K sold $23.7K2026-06-29 · Pham Quang X sold $22.4K2025-09-24 · Szot Matthew K sold $21.0K2025-10-27 · Pham Quang X sold $18.4K2026-05-12 · Pham Quang X sold $17.4K2026-06-04 · Pham Quang X sold $17.2K2025-10-24 · Pham Quang X sold $15.8K2026-05-28 · Pham Quang X sold $14.7K2026-06-10 · Pham Quang X sold $14.7K2026-06-15 · Pham Quang X sold $13.1K2025-10-01 · Pham Quang X sold $12.3K2026-06-16 · Pham Quang X sold $11.5K2026-06-03 · Pham Quang X sold $9.9K2026-06-05 · Pham Quang X sold $9.1K2026-06-23 · Pham Quang X sold $7.3K2025-10-02 · Pham Quang X sold $7.1K2026-05-22 · Pham Quang X sold $6.6K2026-06-25 · Pham Quang X sold $6.4K2026-06-11 · Pham Quang X sold $6.0K2025-09-29 · Pham Quang X sold $5.9K2026-06-17 · Pham Quang X sold $1.6K2026-06-02 · Pham Quang X sold $1.6K2026-05-29 · Pham Quang X sold $1.5K2025-10-06 · Szot Matthew K sold $1.5K2025-09-29 · Szot Matthew K sold $1.4K
INSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows a net $388.3K sold by insiders over 180 days, 11 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Cadrenal Therapeutics, Inc. insiders sold a net $388.3K of stock across 56 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Pham Quang X
Chairman and CEO
SELL
2026-06-29
7,400.0
$22.4K
Pham Quang X
Chairman, CEO and Interim CFO
SELL
2026-06-26
9,029.0
$27.5K
Pham Quang X
Chairman, CEO and Interim CFO
SELL
2026-06-25
2,127.0
$6.4K
Pham Quang X
Chairman, CEO and Interim CFO
SELL
2026-06-23
2,277.0
$7.3K
Pham Quang X
Chairman, CEO and Interim CFO
SELL
2026-06-22
9,167.0
$32.5K
56 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 51 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
VANGUARD CAPITAL MANAGEMENT LLC
50,137.0 sh
$167.5K
GEODE CAPITAL MANAGEMENT, LLC
19,024.0 sh
$63.5K
VANGUARD FIDUCIARY TRUST CO
8,311.0 sh
$27.8K
CoreCap Advisors, LLC
1,285.0 sh
$4.3K
Tower Research Capital LLC (TRC)
1,282.0 sh
$4.3K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
iShares Micro-Cap ETF
$27.0K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$1.4K POSITION · AS OF 2026-03-31
0.0%
Dimensional US Sustainability Core 1 ETF
$6.1K POSITION · AS OF 2026-04-30
0.0%
Fidelity Extended Market Index Fund
$91.0K POSITION · AS OF 2026-02-28
0.0%
U.S. Social Core Equity 2 Portfolio
$3.4K POSITION · AS OF 2026-04-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$61.0K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-13.5M$-11.0M$-7.6M
NET INCOME$-13.2M$-10.7M$-8.4M
EPS (DILUTED)-6.64-8.73-9.29
OPERATING CASH FLOW$-12.6M$-7.4M$-3.5M
CASH$4.0M$10.0M$8.4M$32.6K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →